Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Xemilofiban. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 known ✓ | P05106 | 14/20 | 0.98 |
| ▸ | ITGA2B known ✓ | P08514 | 14/20 | 0.98 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Xemilofiban SCHEMBL5163315 | 0.99 | ITGB3 (1.00) | ITGB3ITGA2BLMNAMAPTTDP1 | |
| Xemilofiban SCHEMBL50663 | 0.99 | ITGB3 (1.00) | ITGB3ITGA2BLMNAMAPTTDP1 | |
| Xemilofiban SCHEMBL27987260 | 0.97 | ITGB3 (0.96) | ITGB3ITGA2B | |
| SCHEMBL7351416 | 0.89 | ITGB3 (0.81) | ITGB3ITGA2BLMNAMAPTTDP1 | |
| SCHEMBL7353828 | 0.86 | ITGB3 (0.77) | ITGB3ITGA2B | |
| SCHEMBL7346572 | 0.86 | ITGB3 (0.77) | ITGB3ITGA2BLMNAMAPTTDP1 | |
| SCHEMBL7346651 | 0.85 | ITGB3 (0.77) | ITGB3ITGA2B | |
| SCHEMBL7348945 | 0.85 | ITGB3 (0.75) | ITGB3ITGA2B | |
| SCHEMBL7355439 | 0.84 | ITGB3 (0.79) | ITGB3ITGA2B | |
| SCHEMBL7346593 | 0.84 | ITGB3 (0.74) | ITGB3ITGA2BLMNAMAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104230758-B | Crystal form of xemilofiban hydrochloride | 合肥合源药业有限公司 | 2017-02-15 | — | — | CN | claimed |
| CN-104230758-A | Crystal form of xemilofiban hydrochloride | HEFEI COSOURCE MEDICNE TECHNOLOGY CO LTD | 2014-12-24 | — | — | CN | claimed |
| CN-104230758-B | Crystal form of xemilofiban hydrochloride | 合肥合源药业有限公司 | 2017-02-15 | — | — | CN | disclosed |
| CN-104230758-B | Crystal form of xemilofiban hydrochloride | 合肥合源药业有限公司 | 2017-02-15 | — | — | CN | disclosed |
| CN-104230758-B | Crystal form of xemilofiban hydrochloride | 合肥合源药业有限公司 | 2017-02-15 | — | — | CN | disclosed |
| US-9353218-B2 | Kit for multifunctional compounds forming crosslinked biomaterials | ANGIOTECH PHARMACEUTICALS, INC. | 2016-05-31 | — | — | US | disclosed |
| CN-104230758-A | Crystal form of xemilofiban hydrochloride | HEFEI COSOURCE MEDICNE TECHNOLOGY CO LTD | 2014-12-24 | — | — | CN | disclosed |
| CN-104230758-A | Crystal form of xemilofiban hydrochloride | HEFEI COSOURCE MEDICNE TECHNOLOGY CO LTD | 2014-12-24 | — | — | CN | disclosed |
| CN-104230758-A | Crystal form of xemilofiban hydrochloride | HEFEI COSOURCE MEDICNE TECHNOLOGY CO LTD | 2014-12-24 | — | — | CN | disclosed |
| CN-104174071-A | COMPOSITIONS AND SYSTEMS FOR FORMING CROSSLINKED BIOMATERIALS AND ASSOCIATED METHODS OF PREPARATION AND USE | ANGIODEVICE INTERNAT GMBH | 2014-12-03 | — | — | CN | disclosed |
| US-20130289235-A1 | MULTIFUNCTIONAL COMPOUNDS FOR FORMING CROSSLINKED BIOMATERIALS AND METHODS OF PREPARATION AND USE | ANGIOTECH PHARMACEUTICALS, INC. (CA) | 2013-10-31 | — | — | US | disclosed |
| WO-2005051452-A2 | POLYMER COMPOSITIONS AND METHODS FOR THEIR USE | ANGIOTECH INTERNATIONAL AG (CH) | 2005-06-09 | — | — | WO | disclosed |
| WO-2005051316-A2 | POLYMER COMPOSITIONS AND METHODS FOR THEIR USE | ANGIOTECH INTERNATIONAL AG (CH) | 2005-06-09 | — | — | WO | disclosed |
| WO-2005051871-A2 | IMPLANTABLE SENSORS AND IMPLANTABLE PUMPS AND ANTI-SCARRING AGENTS | ANGIOTECH INTERNATIONAL AG (CH) | 2005-06-09 | — | — | WO | disclosed |
| WO-2005051483-A2 | ELECTRICAL DEVICES AND ANTI-SCARRING AGENTS | ANGIOTECH INTERNATIONAL AG (CH) | 2005-06-09 | — | — | WO | disclosed |
| WO-2005051444-A2 | SOFT TISSUE IMPLANTS AND ANTI-SCARRING AGENTS | ANGIOTECH INTERNATIONAL AG (CH) | 2005-06-09 | — | — | WO | disclosed |
| WO-2005046516-A2 | MEDICAL IMPLANTS AND ANTI-SCARRING AGENTS | ANGIOTECH INTERNATIONAL AG (CH) | 2005-05-26 | — | — | WO | disclosed |
| US-20050084514-A1 | Combination drug therapy for reducing scar tissue formation | AFMEDICA, INC. (US) | 2005-04-21 | — | — | US | disclosed |
| US-20030118584-A1 | Restoration of platelet aggregation by antibody administration after GPIIB/IIIa antagonist treatment | G.D. SEARLE & CO. | 2003-06-26 | — | — | US | disclosed |
| US-20020177172-A1 | RESTORATION OF PLATELET AGGREGATION BY ANTIBODY ADMINISTRATION AFTER GPIIB/IIIA ANTAGONIST TREATMENT | WESTERN MICHIGAN UNIVERSITY | 2002-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030118584-A1 | Restoration of platelet aggregation by antibody administration after GPIIB/IIIa antagonist treatment | F13B, GP6, FGB | ITGB3 12/4885ITGA2B 10/4885LMNA 2986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.